Renin-Angiotensin-System (RAS)-Acting Agents Industry Growth Expected to Reach $7.72 Billion by 2029 at a CAGR of 5.7% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Renin-Angiotensin-System (RAS)-Acting Agents Market Growth in 2025?
In recent times, there has been a robust growth in the market size of the renin-angiotensin-system (RAS)-acting agents. It is projected to climb from $5.82 billion in 2024 to $6.17 billion in 2025, securing a compound annual growth rate (CAGR) of 6.0%. The growth during the former period can be credited to factors such as the escalating prevalence of hypertension, growth in cardiovascular disease cases, the rise in elderly population, increased cognizance regarding blood pressure management, substantial clinical research backing, and the granting of regulatory approvals for new drugs.
What Is the Forecast for the Renin-Angiotensin-System (RAS)-Acting Agents Market Size Through 2029?
The market for renin-angiotensin-system (RAS)-acting agents is projected to experience substantial growth in the coming years, increasing to $7.73 billion in 2029 with a compound annual growth rate (CAGR) of 5.8%. This anticipated growth during the forecast period is due to factors such as an increasing emphasis on customized therapies, growing demand for fixed-dose combinations, heightened investment in cardiovascular study, expanding healthcare availability in developing markets, and the rising occurrence of diseases related to lifestyle. Noteworthy developments expected in the forecast period include drug development driven by artificial intelligence (AI), nanotechnology-assisted drug delivery, advancements in personalized medicine, application of blockchain for secure clinical data storage, wearable biosensors for monitoring hypertension, and the use of digital twin technology in patient simulation.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp
What are the Key Market Players in Renin-Angiotensin-System (RAS)-Acting Agents Market and How They’re Evolving?
Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.
What Are the Primary Growth Drivers in the Renin-Angiotensin-System (RAS)-Acting Agents Market?
Expected growth in the renin-angiotensin system (RAS)-acting agents market is believed to be driven by the escalating occurrence of hypertension. Hypertension, also known as high blood pressure, is a chronic health issue where the blood pressure against the artery walls is persistently too high. The spike in hypertension is attributed to unhealthy eating habits, especially diets rich in salt and processed foods leading to heightened blood pressure and stress on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents assist in controlling hypertension by managing blood pressure. They work by curbing angiotensin II, a hormone that tightens blood vessels and boosts fluid retention, thereby facilitating vasodilation and reducing blood pressure. As evidence, as of October 2024, the Australian Bureau of Statistics, a government agency in Australia, reported that 11.6% (3.0 million) of Australians were diagnosed with hypertension in 2022, with similar figures for both men (11.7%) and women (11.6%). For these reasons, the escalating prevalence of hypertension is contributing to the expansion of the renin-angiotensin system (RAS)-acting agents market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp
What Are the Leading Segments in the Global Renin-Angiotensin-System (RAS)-Acting Agents Industry?
The renin-angiotensin-system (RAS)-acting agents market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone, Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
What Are the Key Market Trends in the Renin-Angiotensin-System (RAS)-Acting Agents Industry?
Primary businesses in the market for renin-angiotensin system (RAS)-acting agents are concentrating their efforts on the creation of new renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme (ACE) inhibitors. The aim is to maximize effectiveness, decrease adverse reactions, enhance patient adherence, and address conditions like hypertension, heart failure, and kidney disease. ACE inhibitors are medications that manipulate blood pressure and inhibit the enzyme responsible for converting angiotensin I into angiotensin II, a substance that constricts blood vessels. For example, in November 2023, UK pharmaceutical company Proveca Ltd. was granted a pediatric use marketing authorization (PUMA) by the European Commission for Aqumeldi (enalapril maleate) oro-dispersible tablets, which are meant for the treatment of heart failure in children aged newborn to under 18. By blocking the ACE and halting the conversion from angiotensin I to angiotensin II, Aqumeldi relaxes the blood vessels, enhances blood circulation, and reduces the heart’s workload in treatment of pediatric heart failure.
Access The Full Report Here:
What Is the Regional Outlook for the Renin-Angiotensin-System (RAS)-Acting Agents Market?
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23496
This Report Delivers Insight On:
1. How big is the renin-angiotensin-system (ras)-acting agents market, and how is it changing globally?
2. Who are the major companies in the renin-angiotensin-system (ras)-acting agents market, and how are they performing?
3. What are the key opportunities and risks in the renin-angiotensin-system (ras)-acting agents market right now?
4. Which products or customer segments are growing the most in the renin-angiotensin-system (ras)-acting agents market?
5. What factors are helping or slowing down the growth of the renin-angiotensin-system (ras)-acting agents market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
